Drug intelligence / Profile preview

2-(4-chloro-phenylamino)-nicotinic acid

Development stage: Unknown
Modality: Small Molecules

Overview

2-(4-Chloro-phenylamino)-nicotinic acid is a small molecule belonging to the class of pyridinecarboxylic acids. It features a nicotinic acid core with a 4-chlorophenylamino substituent at the 2-position. This compound is considered experimental and has not been approved for any clinical use. There are no known indications, clinical trials, or patents associated with this drug[1][2]. Its mechanism of action and biological targets are not described in available sources.

Other names: 2-(4-CHLORO-PHENYLAMINO)-NICOTINIC ACID

Beyond the preview

Go deeper on 2-(4-chloro-phenylamino)-nicotinic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-(4-chloro-phenylamino)-nicotinic acid.

Explore the full profile